Immunocore Holdings plc (IMCR)

Market Cap	2.88B
Revenue (ttm)	249.43M
Net Income (ttm)	-55.29M
Shares Out	49.73M
EPS (ttm)	-1.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,154
Open	58.37
Previous Close	58.47
Day's Range	57.34 - 58.37
52-Week Range	42.21 - 76.98
Beta	0.89
Analysts	Strong Buy
Price Target	82.50 (+42.56%)
Earnings Date	May 8, 2024

About IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 497
• Stock Exchange: NASDAQ
• Ticker Symbol: IMCR

Financial Performance

In 2023, IMCR's revenue was 249.43 million, an increase of 43.05% compared to the previous year's 174.36 million. Losses were -55.29 million, 5.22% more than in 2022.

Financial numbers in GBP

Analyst Forecast

According to 13 analysts, the average rating for IMCR stock is "Strong Buy." The 12-month stock price forecast is $82.5, which is an increase of 42.56% from the latest price.

Price Target

$82.5

(42.56% upside)

Analyst Consensus: Strong Buy